Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Monza – page 67

2 831 clinical trials in Monza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Monza at a glance
2 831
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 831 trials in Monza

Open in trial search

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Juvenile idiopathic arthritis

Recruiting

Study Comparing Step-up and Step-down Treatment Strategies with Methotrexate and Etanercept for Children with Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Etanercept
  • Sponsor:IRCCS Istituto Giannina Gaslini

Seizure

Recruiting

Study on the Safety and Effectiveness of Alprazolam for Treating Long Seizures in Patients Aged 12 and Older

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alprazolam
  • Sponsor:UCB Biopharma

Myotonic dystrophy

Recruiting

Study on the Effects of Mexiletine for Treating Myotonic Dystrophy Types 1 and 2 in Patients

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings S.A.

Duchenne muscular dystrophy

Recruiting

Long-Term Safety and Efficacy Study of Givinostat for Patients with Duchenne Muscular Dystrophy Previously Treated with Givinostat

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

HER2 gene amplification

Recruiting

Study of zongertinib tablets in patients with advanced solid tumors that have HER2 gene changes

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zongertinib
  • Sponsor:Boehringer Ingelheim Espana S.A.

Sarcoidosis

Recruiting

Study of XTMAB-16 and Prednisolone Sodium Phosphate for Patients with Pulmonary Sarcoidosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:XTMAB-16
  • Sponsor:Xentria Inc.

Osteochondrodysplasia

Recruiting

Study on Long-Term Use of Infigratinib for Children with Achondroplasia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

Relapsing-remitting multiple sclerosis

Recruiting

Study Comparing the Effects of Ozanimod and Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Fingolimod
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Atrial fibrillation

Recruiting

Study Comparing Single and Dual Antiplatelet Therapy with Clopidogrel and Acetylsalicylic Acid for Patients with Atrial Fibrillation Undergoing Left Atrial Appendage Closure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fondazione Toscana Gabriele Monasterio

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Small cell lung cancer

Recruiting

Study of Atezolizumab and Chemotherapy for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Monza

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments and novel approaches for lymphoma management. Studies include targeted therapies and immunotherapy combinations.

  • NSCLC Treatment Studies
  • Lymphoma Therapy Innovations
  • Breast Cancer Research

Advanced investigations into personalized treatment approaches for various cancer types using targeted therapies and immunological interventions.

02 Autoimmune Conditions

Research focusing on psoriatic arthritis and multiple sclerosis, evaluating novel biological treatments and their effectiveness in managing disease progression.

  • Inflammatory Disease Studies
  • Biomarker Research
  • Treatment Response Evaluation

Comprehensive studies examining new therapeutic approaches for chronic autoimmune conditions.

03 Infectious Diseases

Vaccine development studies targeting Herpes Zoster and Cytomegalovirus, focusing on prevention and immune response in different age groups.

  • Vaccine Efficacy Studies
  • Long-term Immunity Research
  • Viral Prevention Strategies

Advanced clinical trials evaluating new vaccination approaches and therapeutic strategies.

04 Cardiovascular Studies

Innovative research on heart failure prevention and pulmonary arterial hypertension, testing new therapeutic combinations and treatment approaches.

  • Preventive Cardiology
  • Hypertension Management
  • Drug Combination Studies

Investigation of novel therapeutic strategies for cardiovascular disease management and prevention.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.